429
Participants
Start Date
November 30, 2002
Primary Completion Date
December 31, 2003
5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
Boehringer Ingelheim Investigational Site, Berlin
MEDARS GmbH, Berlin
Boehringer Ingelheim Investigational Site, Bonn
Boehringer Ingelheim Investigational Site, Frankfurt am Main
Inamed Research GmbH & Co. KG, Gauting
Pneumologisches Forschungsinstitut GmbH, Großhansdorf
Pneumologisches Forschungsinstitut GmbH am Krankenhaus, Hamburg
Boehringer Ingelheim Investigational Site, Hanover
Universitätsklinikum Schleswig-Holstein, Kiel
ClinPharm International GmbH & Co. KG, Leipzig
Neurologische Klinik der Otto-von-Guericke-Universität, Magdeburg
Johannes-Gutenberg-Universität Mainz, Mainz
Boehringer Ingelheim Investigational Site, Minden
Medizinische Klinik III, Moers
Boehringer Ingelheim Investigational Site, München
Abt. Lungen- und Bronchialheilkunde, Schmallenberg
Boehringer Ingelheim Investigational Site, Steinfurt
Ospedale Generale Provinciale Mazzoni, Ascoli Piceno
Dip. di Medicina Interna e Medicina Specialistica, Catania
U. O. di Fisiopatologia Respiratoria, Ferrara
Ospedale S. Martino, Genova
U. O. di Pneumologia e Servizio di Fisiopatologia Resp., Milan
IRCCS Policlinico San Matteo, Pavia
U. O. C di Pneumologia, Roma
Ospedale Silvestrini, San Sisto (pg)
U. O. di Pneumologia, Trieste
Hydromed Hospital, Bloemfontein
UCT Lung Institute, Cape Town
1 Military Hospital, Pretoria
Tygerberg Hospital, Tygerberg
Universitätskliniken Basel, Basel
Ospedale San Giovanni, Bellinzona
Boehringer Ingelheim Investigational Site, Davos
Boehringer Ingelheim Investigational Site, Laufen
Boehringer Ingelheim Investigational Site, Locarno
Ospedale Regionale, Lugano
Boehringer Ingelheim Investigational Site, Münchenstein
Kantonsspital St. Gallen, Sankt Gallen
Lead Sponsor
Boehringer Ingelheim
INDUSTRY